New peptide drugs could take aim at a broader range of proteins that cause certain cancers, viral infections, and brain ...

Votoplam (PTC518) for Huntington's Disease shows promising phase 2 results; a key FDA meeting in Q4 2025 could enable ...

Neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis, are among the most ...

Researchers led by the nonprofit 4YouandMe and Mount Sinai want to identify second-site suppressor mutations as drug targets ...

Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 ...

Rap icon Eminem reveals that a near-fatal drug overdose was the wake-up call that finally inspired him to get sober after ...

A community walk bringing awareness for Huntington’s Disease is back in Eau Claire for their ninth straight year. As part of ...

The Wisconsin Chapter of the Huntington’s Disease Society of America will be hosting the 2025 HDSA Madison Team Hope Walk on ...

PepMLM generates binders to challenging therapeutic targets across cancer and neurological disease using protein sequence and ...

Wisconsin's chapter of the Huntington's Disease Society of America is set to host the 2025 Team Hope Walk at McKee Farms Park ...

A series of digital tests, carried out via a smartphone app, could enhance the detection of disease progression in Huntington’s disease and improve the efficiency of clinical trials.

If rates of Huntington’s disease across Scotland are similar to the north, around 800 people are manifesting signs of the condition, and almost 2,500 have the gene, according to research.